NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.) ニュ―ロクライン・バイオサイエンシズ

 NBIXのチャート


 NBIXの企業情報

symbol NBIx
会社名 Neurocrine Biosciences Inc. (ニュ―ロクライン・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ニューロクライン・バイオサイエンシス(Neurocrine Biosciences Inc)は神経と内分泌関連疾患及び障害の治療薬の発見・開発・商業化に従事する企業。同社の薬品候補は子宮内膜症、ストレス関連疾患、疼痛、糖尿病、不眠症、及び他の神経と内分泌関連疾患及び障害などの製薬市場に提供する。同社は各自の研究・開発段階にある11のプログラムを持ち、そのうち、6つのプログラムは臨床開発段階にある。同社は6つのプログラムのためのコラボレーションを締結した。同社の主要な臨床開発プログラム「elagolix」は子宮内膜症治療用の薬剤候補。同社の製品ポートフォリオは「Elagolix」、小胞モノアミントランスポーター2阻害剤(VMAT2)、コルチコトロピン遊離因子タイプ2(CRF2)ペプチド・アゴニストウロコルチン、コルチコトロピン遊離因子タイプ1(CRF1)拮抗薬(561679)、コルチコトロピン遊離因子タイプ1(CRF1)拮抗薬(586529)、Gタンパク質共役型受容体119(GPR119)、VMAT2、性腺刺激ホルモン放出ホルモン(GnRH)拮抗薬、抗てんかん薬、Gタンパク質共役受容体と「Indiplon」などを含む。   ニュ―ロクライン・バイオサイエンシズは米国のバイオ医薬品メ―カ―。主に、神経及び内分泌関連疾患や障害である、子宮内膜症、糖尿病、睡眠障害、疼痛、ストレス性障害、てんかんなどの治療薬の臨床・開発に従事する。カリフォルニア州サンディエゴに拠点を置き、世界的に事業を展開。   Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
本社所在地 12780 El Camino Real San Diego CA 92130 USA
代表者氏名 William H. Rastetter ウィリアムH.ラスターセッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-617-7600
設立年月日 33604
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 400人
url www.neurocrine.com
nasdaq_url https://www.nasdaq.com/symbol/nbix
adr_tso
EBITDA EBITDA(百万ドル) -30.46900
終値(lastsale) 112.3
時価総額(marketcap) 10159709240.3
時価総額 時価総額(百万ドル) 9776.119
売上高 売上高(百万ドル) 323.28200
企業価値(EV) 企業価値(EV)(百万ドル) 9646.264
当期純利益 当期純利益(百万ドル) -51.96200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neurocrine Biosciences Inc. revenues increased from $6.3M to $168M. Net loss decreased 65% to $47.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment income net increase from $1.9M to $6.3M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.58 to -$0.53.

 NBIXのテクニカル分析


 NBIXのニュース

   Neurocrine Biosciences Announces Repurchase of Convertible Notes  2020/11/19 13:00:00 PR Newswire
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Neurocrine Biosciences to Present at Upcoming Healthcare Conferences  2020/11/09 14:00:00 PR Newswire
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business Development and Strategy…
   Neurocrine Biosciences Q3 2020 Earnings Preview (NASDAQ:NBIX)  2020/11/08 17:02:31 Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate i
   Biogen, UnitedHealth: 5 Top Stock Gainers for Wednesday  2020/11/04 18:03:11 The Street
Super Micro Computer, Biogen, Neurocrine Biosciences, Supernus Pharmaceuticals and UnitedHealth.
   Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020  2020/09/11 15:34:00 PR Newswire
SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS® (opicapone) capsules decreased "off" time and increased "on" time without troublesome…
   Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference  2020/09/08 20:01:00 PR Newswire
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial…
   Looking Into Neurocrine Biosciences's Return On Capital Employed  2020/08/28 10:11:00 Benzinga
Looking at Q2, Neurocrine Biosciences (NASDAQ: NBIX) earned $76.60 million, a 30.05% increase from the preceding quarter. Neurocrine Biosciences also posted …
   Neurocrine Biosciences und Takeda kündigen Zusammenarbeit bei der Entwicklung und Vermarktung möglicher Therapien für psychische Störungen an  2020/06/16 21:25:00 Business Wire
SAN DIEGO und OSAKA, Japan--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) und die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda”) gaben heute eine strategische Zusammenarbeit bei der Entwicklung und Vermarktung von Wirkstoffen aus der Takeda-Pipeline der im frühen bis mittleren Entwicklungsstadium befindlichen Psychatrie-Medikamente bekannt. Im Rahmen dieser Kooperation gewährte Takeda Neurocrine Biosciences insbesondere eine Exklusivlizenz für sieben Pipeline
   Neurocrine Biosciences et Takeda annoncent une collaboration pour le développement et la mise sur le marché de thérapies potentielles contre les troubles psychiatriques  2020/06/16 20:04:00 Business Wire
SAN DIEGO & OSAKA, Japon--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) et Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (« Takeda ») annoncent ce jour une collaboration stratégique pour le développement et la mise sur le marché de composés en phase initiale et intermédiaire du pipeline psychiatrique de Takeda. Takeda a accordé une licence exclusive à Neurocrine Biosciences pour sept programmes de pipeline, dont trois actifs en phase clinique pour la schizophrénie, la
   Neurocrine Biosciences und Takeda kündigen Zusammenarbeit bei der Entwicklung und Vermarktung möglicher Therapien für psychische Störungen an  2020/06/16 21:25:00 Business Wire
SAN DIEGO und OSAKA, Japan--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) und die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda”) gaben heute eine strategische Zusammenarbeit bei der Entwicklung und Vermarktung von Wirkstoffen aus der Takeda-Pipeline der im frühen bis mittleren Entwicklungsstadium befindlichen Psychatrie-Medikamente bekannt. Im Rahmen dieser Kooperation gewährte Takeda Neurocrine Biosciences insbesondere eine Exklusivlizenz für sieben Pipeline
   Neurocrine Biosciences et Takeda annoncent une collaboration pour le développement et la mise sur le marché de thérapies potentielles contre les troubles psychiatriques  2020/06/16 20:04:00 Business Wire
SAN DIEGO & OSAKA, Japon--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) et Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (« Takeda ») annoncent ce jour une collaboration stratégique pour le développement et la mise sur le marché de composés en phase initiale et intermédiaire du pipeline psychiatrique de Takeda. Takeda a accordé une licence exclusive à Neurocrine Biosciences pour sept programmes de pipeline, dont trois actifs en phase clinique pour la schizophrénie, la
   Neurocrine Biosciences y Takeda anuncian una colaboración para desarrollar y comercializar posibles tratamientos para trastornos psiquiátricos  2020/06/16 16:25:00 Business Wire
SAN DIEGO y OSAKA, Japón--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) y Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) («Takeda») acaban de anunciar una colaboración estratégica para desarrollar y comercializar compuestos en la línea de productos para psiquiatría en fase inicial a media de Takeda. Específicamente, Takeda concede una licencia exclusiva a Neurocrine Biosciences para siete programas en desarrollo, incluidos tres activos en fase clínica para la esquizofre
   Neurocrine Biosciences e Takeda anunciam colaboração para desenvolver e comercializar potenciais terapias para distúrbios psiquiátricos  2020/06/16 15:57:00 Business Wire
SAN DIEGO e OSAKA, Japão--(BUSINESS WIRE)--A Neurocrine Biosciences, Inc. (Nasdaq:NBIX) e a Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) anunciaram hoje uma colaboração estratégica para desenvolver e comercializar produtos de psiquiatria em estágio inicial e intermediário da Takeda. Especificamente, a Takeda concedeu uma licença exclusiva à Neurocrine Biosciences para sete programas, incluindo três ativos de estágio clínico para esquizofrenia, depressão resistente ao tra
   Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders  2020/06/16 11:00:00 Business Wire
Neurocrine Biosciences and Takeda announced a strategic collaboration for compounds in Takeda’s early-to-mid-stage psychiatry pipeline.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ニュ―ロクライン・バイオサイエンシズ NBIX Neurocrine Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)